Cygencia recently announced it raised $1.4 million in a seed fund investment round, that was led by the global capital investor SOSV.

Acceleration

The funding will accelerate the validation of CyGencia’s exclusive technology, which allows and enables safe, targeted, and affordable intercellular drug delivery.

Dr. Nusrat Sanghamitra, Co-founder and CEO of CyGenica said ‘The challenge of delivering drugs for cancer and genetic therapies, be it genes/RNAs/CRISPRs across cell membranes without damaging the cells and triggering an adverse immune response remains a complex hurdle in the pharmaceutical industry.’

Cygencia’s ground-breaking technology will function like a ‘flash drive’, acting as a nanomachine that can carry a mass amount of molecular information such as drugs and genetic therapeutics in an efficient, targeted manner without any toxicity and minimum immunogenicity.

Sami Mikati, a life sciences angel investor, said ‘Nusrat is solving one of the most valuable problems in therapeutics today, her approach is completely novel, which is a reflection of her interdisciplinary background.’

Investment Utilisation

Cygencia plans to utilise the investment further by establishing itself as a key partner of biopharmaceutical companies for the development of cutting-edge therapeutics for cancer and rare diseases to improve patient’s quality of life.

“This current financing round has brought a diversified international network onboard. This will help de-risk our technology, expand our leadership team and take us significantly closer to our goal.” said Dr. Sanghamitra.

‘This will revolutionize drug delivery and lead to better patient outcomes.’

Other investors participating in the round included the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io, and angel investors Sharaf Yamani and Sami Mikati.

David Rowan the Founder of Voyagers.io added “Life-changing healthcare innovation isn’t only coming out of the established life-science hubs.’